ChiCTR2200065591 版本V1.2 版本创建时间2023/11/09 14:24:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200065591 

最近更新日期:

Date of Last Refreshed on:

2023-05-06 10:32:46 

注册时间:

Date of Registration:

2022-11-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

导航精准定位下重复经颅磁刺激治疗非酒精性脂肪性肝病患者有效性的随机对照试验

Public title:

The effects of repetitive transcranial magnetic stimulation in patients with nonalcoholic fatty liver disease: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

导航精准定位下重复经颅磁刺激治疗非酒精性脂肪性肝病患者有效性的随机对照试验

Scientific title:

A randomized controlled trial of the efficacy of repetitive transcranial magnetic stimulation in the treatment of patients with nonalcoholic fatty liver disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙磊 

研究负责人:

张秋玲 

Applicant:

Lei Sun 

Study leader:

Qiuling Zhang 

申请注册联系人电话:

Applicant telephone:

+86 13605804606

研究负责人电话:

Study leader's
telephone:

+86 13867485066

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sl13605804606@163.com

研究负责人电子邮件:

Study leader's E-mail:

nfmkzql@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市拱墅区温州路126号

研究负责人通讯地址:

浙江省杭州市拱墅区温州路126号

Applicant address:

126 Wenzhou Road, Gongshu District, Hangzhou, Zhejiang

Study leader's address:

126 Wenzhou Road, Gongshu District, Hangzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

杭州师范大学附属医院

Applicant's institution:

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

研究负责人所在单位:

杭州师范大学附属医院

Affiliation of the Leader:

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022(E2)-HS-154

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

杭州师范大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of Affiliated Hospital of Hangzhou Normal University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-10-14 00:00:00

伦理委员会联系人:

干文韬

Contact Name of the ethic committee:

Wentao Gan

伦理委员会联系地址:

浙江省杭州市拱墅区温州路126号

Contact Address of the ethic committee:

126 Wenzhou Road, Gongshu District, Hangzhou, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 88303417

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

杭州师范大学附属医院

Primary sponsor:

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

研究实施负责(组长)单位地址:

浙江省杭州市拱墅区温州路126号

Primary sponsor's address:

126 Wenzhou Road, Gongshu District, Hangzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

杭州

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

杭州师范大学附属医院

具体地址:

拱墅区温州路126号

Institution
hospital:

the Affiliated Hospital of Hangzhou Normal University

Address:

126 Wenzhou Road, Gongshu District

经费或物资来源:

浙江省重点项目

Source(s) of funding:

Zhejiang Provincial key program Project

研究疾病:

非酒精性脂肪性肝病  

Target disease:

nonalcoholic fatty liver disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1. 明确导航精确定位下重复经颅磁刺激干预对超重或肥胖NAFLD患者肝脏脂肪含量水平、食物渴求水平、进食行为的影响及长期疗效。 2. 考察导航精确定位下重复经颅磁刺激干预对超重或肥胖NAFLD患者血脂紊乱、胰岛素抵抗、人体测量学指标等指标的影响。 3. 探索导航精确定位下重复经颅磁刺激干预对超重或肥胖NAFLD患者大脑静息功能网络连接的影响。  

Objectives of Study:

1. To determine the effects of repeated transcranial magnetic stimulation intervention on liver fat, food craving, energy intake and long-term efficacy in overweight or obese NAFLD patients. 2. To investigate the effects of repeated transcranial magnetic stimulation intervention on blood lipid disorder, insulin resistance and anthropometric indicators in overweight or obese NAFLD patients. 3. To explore the effects of repeated transcranial magnetic stimulation intervention on cerebral resting-state functional connectivity in overweight or obese NAFLD patients under precise navigation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄 18-60 岁(含临界值),BMI≥24kg/m2,性别、民族不限,右利手;
2. 随机化前经MRI-PDFF诊断为NAFLD患者;
3. 无饮酒史或既往史,女性平均纯酒精摄入<10g/天,男性平均纯酒精摄入<20g/天;
4. 在入组前没有接受过TMS刺激治疗;
5. 愿意签署知情同意书,并能够理解本试验的程序和方法,愿意严格遵守临床试验方案完成本试验;
6. 在参与研究之前,必须报告体重稳定(±5%)3个月。

Inclusion criteria

1. 18-60 years old, BMI >= 24kg/m2, regardless of gender and nationality, right-handed;
2. NAFLD patients diagnosed by MRI-PDFF before randomization;
3. alcohol intake of women is less than 10g/day, and alcohol intake of men is less than 20g/day;
4. No TMS stimulation treatment before;
5. Willing to sign the informed consent form, understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial protocol to complete this trial
6. Weight stability (± 5%) must be reported for 3 months before participating in the study

排除标准:

1. 既往头部受伤或癫痫病史;
2. 身体金属植入物,起搏器和任何其他MRI或rTMS禁忌症;
3. 3个月以内体重波动>5%者;
4. 目前正患有精神疾病或正在服用抗精神病类药物;
5. 近期使用减肥药或极低热量饮食者;
6. 饮食失调或物质依赖者;
7. 存在糖尿病或不稳定的心血管疾病;
8. 怀孕或母乳喂养者
9. 脑部MRI显示异常结果。

Exclusion criteria:

1. Head injury or epilepsy;
2. Metal implants ;Pacemakers and any other contraindications to MRI or rTMS;
3. Weight fluctuation>5% within 3 months;
4. Currently suffering from mental illness or taking antipsychotic drugs;
5. People who use diet pills or very low-calorie diet recently;
6. Eating disorders or material dependence;
7. Presence of diabetes or unstable cardiovascular disease;
8. Pregnant or breast fed;
9. Brain MRI showed abnormal results.

研究实施时间:

Study execute time:

From 2022-11-30 00:00:00 To 2024-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-11-30 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

rTMS刺激组

样本量:

15

Group:

rTMS group

Sample size:

干预措施:

rTMS刺激

干预措施代码:

Intervention:

transcranial magnetic stimulation

Intervention code:

组别:

假刺激对照组

样本量:

15

Group:

sham control group

Sample size:

干预措施:

假刺激

干预措施代码:

Intervention:

sham stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

杭州师范大学附属医院 

单位级别:

三级医院 

Institution
hospital:

the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

MRI-PDFF

指标类型:

主要指标

Outcome:

MRI-PDFF

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝脏弹性成像

指标类型:

主要指标

Outcome:

Fibroscan

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

主要指标

Outcome:

body weight

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BMI

指标类型:

次要指标

Outcome:

Body Mass Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围

指标类型:

次要指标

Outcome:

waist circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂代谢

指标类型:

次要指标

Outcome:

lipid metabolism

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素抵抗模型

指标类型:

次要指标

Outcome:

HOMA-IR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

能量摄入水平

指标类型:

次要指标

Outcome:

energy intake

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

食物渴求水平

指标类型:

次要指标

Outcome:

Food craving

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑功能连接

指标类型:

次要指标

Outcome:

brain network activity

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

分层随机化(分配序列是由一名没有参与试验的研究人员创建的,在分配任务发生之前,该序列对研究人员是隐藏的。)

Randomization Procedure (please state who generates the random number sequence and by what method):

Stratified randomization (The allocation sequence was created by a researcher with no involvement in the trial, and the sequence concealed from study personnel until assignment occurred.)

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表研究论文或做学术会议报告

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish research papers or present at conference

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

干预组与对照组研究对象招募后收集相关检查及量表数据,干预后及随访过程中再次对两组调查对象分别收集相关检查及量表数据。调查数据将加密保存在不联网的电脑上。仅授权的项目人员能接触到研究数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The participants in the intervention group and the control group will be collected relevant examination and data. After the intervention and during follow-up, the data will be collected again for the two groups of participants. All data will be stored in an internet-free laptop with secured passcode protected. Only authorized staff can access the database.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-09 15:09:28